Furthermore, Le and colleagues launched a clinical trial across 12 different tumor types, substantiating that patients with advanced mismatch repair-deficient cancers greatly benefited from PD-1 blockade therapy regardless of cancer type (Le et al. 2017). Here, PDCD1 is linked to neoplasm.